Overview

The global Continuous Glucose Monitoring (CGM) Market was valued at USD 12.36 billion in 2025 and is projected to reach USD 41.96 billion by 2034, growing at a CAGR of 14.5% during 2026–2034. The market is driven by rising diabetes prevalence, growing adoption of wearable glucose monitoring devices, and increasing demand for real-time glucose tracking. The market is shifting from Type 1-diabetes-focused adoption toward broader Type 2 and pre-diabetic populations, supported by the 2024 launch of over-the-counter CGM devices from Dexcom and Abbott that do not require a prescription. Leading manufacturers are investing in longer sensor wear times, dual-analyte sensing that combines glucose and ketone monitoring, and deeper integration with automated insulin delivery systems, while AI-powered analytics are increasingly used for pattern detection, fluctuation forecasting, and predictive hypoglycemia alerts. Government and regulatory factors, including expanding reimbursement coverage from national payers and the U.S. Food and Drug Administration's clearance pathway for integrated continuous glucose monitor (iCGM) systems, continue to shape market access and adoption. Broader insurance coverage for Type 2 diabetes patients and growing recognition of CGM's clinical value in reducing hypoglycemia risk are accelerating uptake beyond the traditional Type 1 diabetes and insulin-dependent patient base. By region, North America held the largest share of the market in 2025, supported by strong reimbursement structures, advanced healthcare infrastructure, and the presence of leading manufacturers including Dexcom, Abbott, and Medtronic. Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by improving healthcare infrastructure, rising disposable income, and increasing diabetes prevalence across China, India, and Japan.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Expansion of Over-the-Counter CGM Access Redefining the Addressable Market

• The 2024 U.S. launch of over-the-counter CGM devices from Dexcom (Stelo) and Abbott (Lingo and Libre Rio) removed the prescription requirement for non-insulin Type 2 diabetes users and non-diabetic wellness consumers, opening access to an estimated 25 million additional potential U.S. users.
• Manufacturers are increasingly blurring the line between medical necessity and consumer wellness monitoring, with OTC CGM platforms targeting pre-diabetic and health-conscious non-diabetic populations alongside traditional diabetes patients.
• AI-powered analytics platforms are being layered onto CGM data streams to support pattern detection, glucose fluctuation forecasting, and timely hypoglycemia alerts, enhancing clinical and consumer value beyond raw glucose readings.
• Abbott secured CE Mark approval for Libre Duo and Libre Duo 10 Day, the first dual glucose-ketone sensing technology, with FDA approval expected in the second half of 2026, expanding CGM functionality beyond glucose-only monitoring.

 

KEY MARKET DRIVER

Rising Global Diabetes Prevalence and Expanding Reimbursement is the Key Driver

• The escalating global prevalence of diabetes, driven by aging populations, rising obesity rates, and urbanization, continues to expand the addressable patient population for continuous glucose monitoring devices.
• Expanding reimbursement coverage from national payers and insurers, particularly for Type 2 diabetes patients who do not use insulin, is removing a key adoption barrier and broadening the eligible user base.
• Growing clinical evidence demonstrating CGM's value in reducing hypoglycemia risk and improving glycemic control is reinforcing physician recommendations and payer coverage decisions across both Type 1 and Type 2 diabetes populations.
• Dexcom received FDA clearance for a 15-day wear CGM sensor, extending wear time from its previous 10-day sensors, with a full commercial launch planned for the second half of the year to help narrow the wear-time gap with competitor Abbott.

 

KEY MARKET OPPORTUNITY

Deeper Integration with Automated Insulin Delivery Systems Creating Significant Opportunity

• Growing adoption of automated insulin delivery systems that combine CGM data with algorithm-driven insulin dosing is creating significant opportunities for manufacturers to deepen platform integration and recurring revenue through connected ecosystems.
• Expanding accessibility of CGM devices in low- and middle-income countries presents substantial untapped demand as healthcare infrastructure and diabetes awareness improve globally.
• Emerging non-invasive and minimally invasive sensing technologies, including implantable long-wear sensors and intradermal biosensors, are opening new product categories that could reduce patient burden and expand addressable use cases.
• Insulet announced plans for its Omnipod 5 automated insulin delivery system to pair with Abbott’s FreeStyle Libre 3 Plus CGM, expanding interoperability beyond the currently supported Libre 2 Plus sensor.

Continuous Glucose Monitoring Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Sensors held the largest market share in 2025, supported by the recurring replacement cycle inherent to CGM sensors, which typically require replacement every 10–15 days depending on the device. The frequent replacement requirement generates significantly higher sales volumes compared with transmitters or receivers and creates a recurring revenue stream for manufacturers. Growing adoption of CGM systems among patients requiring continuous glucose monitoring further supports sustained demand for sensor components.

 

Transmitters are projected to grow at the fastest CAGR during the forecast period, driven by continued innovation in wireless connectivity, miniaturization, and extended battery life. Advances in transmitter design are improving device performance, convenience, and integration with smartphones and other connected healthcare platforms. These technological improvements are encouraging upgrade cycles among existing CGM users while supporting demand for newer, more compact, and longer-lasting transmitter solutions.

 

Component categories include

                 ·           Sensors (Dominating Segment)

                 ·           Transmitters (Highest CAGR Segment)

                 ·           Receivers & Applicators

 

Analysis by Connectivity

Bluetooth remained the leading connectivity standard in 2025, supported by widespread smartphone compatibility, low power consumption, and reliable wireless communication, making it the preferred option for consumer-facing CGM applications. Its broad device compatibility enables seamless transmission of glucose readings to smartphones and connected devices. Growing adoption of mobile health applications and remote glucose monitoring further supports Bluetooth-based connectivity in CGM systems.

 

Cellular connectivity is projected to grow at the fastest CAGR during the forecast period, supported by rising demand for remote patient monitoring in professional and high-risk care settings. It enables real-time glucose data sharing with clinicians without dependence on a paired smartphone, improving continuous monitoring and supporting timely clinical intervention. Increasing adoption of connected healthcare solutions and demand for uninterrupted data transmission are further supporting the use of cellular connectivity in CGM systems.

 

Connectivity categories include

                 ·           Bluetooth (Dominating Segment)

                 ·           Cellular (Highest CAGR Segment)

                 ·           NFC

 

Analysis by Indication

Type 1 Diabetes held the largest market position in 2025, supported by the established clinical necessity of continuous glucose monitoring among insulin-dependent patients requiring tight glycemic control. CGM systems provide continuous glucose readings that support insulin management, glucose trend tracking, and timely adjustments to therapy. Established clinical adoption and increasing awareness of the benefits of continuous monitoring continue to sustain demand among Type 1 diabetes patients.

 

Type 2 Diabetes is projected to grow at the fastest CAGR during the forecast period, supported by improved insurance coverage, rising Type 2 diabetes prevalence, and the introduction of over-the-counter CGM options targeting non-insulin users. Broader access to affordable and user-friendly devices is expanding CGM adoption among Type 2 diabetes patients. Growing awareness of continuous glucose monitoring for glucose management and lifestyle tracking is further supporting market expansion.

 

Indication categories include

                 ·           Type 1 Diabetes (Dominating Segment)

                 ·           Type 2 Diabetes (Highest CAGR Segment)

 

Analysis by Distribution Channel

Pharmacies held the largest market position in 2025, supported by their established role in dispensing prescription CGM devices and providing patient counseling and product guidance. Their widespread retail presence and direct interaction with patients make pharmacies an important distribution channel for CGM products. Continued demand for prescription-based monitoring solutions further strengthens their role in the CGM market.

 

E-commerce channels are projected to grow at the fastest CAGR during the forecast period, driven by the direct-to-consumer distribution model adopted for over-the-counter CGM products and rising consumer comfort with purchasing health devices online. Online platforms provide convenient access to CGM products while enabling consumers to compare devices, features, and prices. Growing digital health adoption and expanding availability of over-the-counter CGM products are further supporting online sales.

 

Distribution Channel categories include

                 ·           Pharmacies (Dominating Segment)

                 ·           E-commerce (Highest CAGR Segment)

                 ·           Others 

By Region

Global Continuous Glucose Monitoring Regional Analysis

Regional Analysis

North America held the leading market position in 2025, supported by strong reimbursement structures, advanced healthcare infrastructure, and high awareness among diabetic patients. The United States represents the region’s largest and most developed CGM market, supported by leading manufacturers such as Dexcom, Abbott, and Medtronic, broad healthcare access, and growing adoption of over-the-counter CGM products. Canada is supported by an established healthcare system, increasing diabetes management needs, and expanding adoption of digital and remote monitoring technologies. Mexico is experiencing growing demand for CGM solutions as diabetes prevalence increases and healthcare providers increasingly adopt advanced glucose monitoring technologies. Continued innovation across the region, including longer-wear sensors and dual-analyte sensing, is reshaping competitive dynamics and expanding CGM applications.

 

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by improving healthcare infrastructure, rising disposable income, increasing diabetes prevalence, and growing adoption of connected healthcare technologies. China represents a major regional market, supported by expanding healthcare access, a large diabetic population, and increasing adoption of advanced glucose monitoring solutions. India is witnessing growing demand for CGM systems as diabetes management becomes more technology-driven and awareness of continuous monitoring increases. Japan has a mature healthcare system and strong adoption of medical technologies, supporting demand for innovative and reliable CGM solutions. South Korea is also emerging as an important market, supported by advanced digital healthcare infrastructure, high smartphone penetration, and increasing interest in remote and connected diabetes management. Regional manufacturers are further expanding access to more affordable CGM solutions across the region.

 

Countries and Regions Covered

North America (Dominating Region)

o  United States (Largest Country Market)

o  Canada

o  Mexico

Asia-Pacific (Fastest Growing Region)

o  China (Largest Country Market)

o  India (Fastest-Growing Country Market)

o  Japan

o  South Korea

o  Rest of Asia-Pacific

Europe

o  Germany (Largest Country Market)

o  United Kingdom

o  France

o  Italy

o  Rest of Europe

Latin America

o  Brazil (Largest Country Market)

o  Chile (Fastest-Growing Country Market)

o  Rest of Latin America

Middle East & Africa

o  Saudi Arabia (Largest Country Market)

o  United Arab Emirates (Fastest-Growing Country Market)

o  Rest of Middle East & Africa

Market Share

The Global Continuous Glucose Monitoring Market is consolidated, with Abbott, Dexcom, and Medtronic accounting for the majority of global shipments and maintaining strong positions through broad CGM portfolios, established distribution networks, and integration with insulin delivery systems. Senseonics differentiates itself through its long-wear implantable CGM technology, while Roche and A. Menarini Diagnostics strengthen their positions through established diabetes diagnostics portfolios and CGM-related offerings. I-SENS, Medtrum Technologies, Nemaura Medical, and Zhejiang POCTech compete through cost-effective CGM solutions, sensor innovation, wearable platforms, and expansion across Asian and international markets. Competition is centered on sensor accuracy, wear duration, affordability, connectivity, and integration with automated insulin delivery systems, while companies are increasingly targeting broader Type 2 diabetes and non-insulin-using populations. Strategic priorities across these players include extending sensor life, expanding geographic availability, developing integrated glucose-management ecosystems, and improving affordability to accelerate CGM adoption beyond intensive insulin users.

 

Key Players

                 ·           Dexcom, Inc. (US)

                 ·           Abbott Laboratories (US)

                 ·           Medtronic plc (Ireland)

                 ·           Senseonics Holdings, Inc. (US)

                 ·           F. Hoffmann-La Roche Ltd (Switzerland)

                 ·           Menarini Diagnostics S.r.l. (Italy)

                 ·           I-SENS, Inc. (South Korea)

                 ·           Medtrum Technologies Inc. (China)

                 ·           Nemaura Medical Inc. (UK)

                 ·           Zhejiang POCTech Co., Ltd. (China)

 

Recent Market Developments

• November 2025: Dexcom launched the G7 15 Day CGM in the U.S. on December 1, 2025, offering up to 15.5 days of sensor wear. The launch strengthens Dexcom’s position in the Continuous Glucose Monitoring Market by improving user convenience, reducing sensor replacement frequency, and expanding access through DME providers and Medicare coverage.
• June 2026: Dexcom announced the acquisition of Nutrisense in June 2026 and launched early access to its redesigned Stelo app for non-insulin users. The move strengthens Dexcom’s position in the Continuous Glucose Monitoring Market by expanding CGM-based nutrition and metabolic health services beyond traditional diabetes management.
• March 2025: Senseonics received FDA approval for Eversense 365 and launched the CGM with commercial partner Ascensia Diabetes Care in 2025. The launch strengthens Senseonics’ position in the Continuous Glucose Monitoring Market by offering a 365-day implantable CGM, extending sensor wear duration and reducing the frequency of sensor replacement.

Frequently Asked Questions